CN101883565A - 用于腹主动脉瘤治疗的三唑并[4，5-d]嘧啶化合物 - Google Patents

用于腹主动脉瘤治疗的三唑并[4，5-d]嘧啶化合物 Download PDF

Info

Publication number
CN101883565A
CN101883565A CN2008801189070A CN200880118907A CN101883565A CN 101883565 A CN101883565 A CN 101883565A CN 2008801189070 A CN2008801189070 A CN 2008801189070A CN 200880118907 A CN200880118907 A CN 200880118907A CN 101883565 A CN101883565 A CN 101883565A
Authority
CN
China
Prior art keywords
compound
treatment
thrombus
day
difluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801189070A
Other languages
English (en)
Chinese (zh)
Inventor
J-B·米切尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN101883565A publication Critical patent/CN101883565A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2008801189070A 2007-12-03 2008-12-02 用于腹主动脉瘤治疗的三唑并[4，5-d]嘧啶化合物 Pending CN101883565A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301616.4 2007-12-03
EP07301616 2007-12-03
PCT/SE2008/051386 WO2009072967A1 (en) 2007-12-03 2008-12-02 Triazolo [4,5-d] pyrimidine compounds for treatment of abdominal aortic aneurysms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410139401.5A Division CN103919781A (zh) 2007-12-03 2008-12-02 用于腹主动脉瘤治疗的三唑并[4, 5-d]嘧啶化合物

Publications (1)

Publication Number Publication Date
CN101883565A true CN101883565A (zh) 2010-11-10

Family

ID=40717966

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2008801189070A Pending CN101883565A (zh) 2007-12-03 2008-12-02 用于腹主动脉瘤治疗的三唑并[4，5-d]嘧啶化合物
CN201410139401.5A Pending CN103919781A (zh) 2007-12-03 2008-12-02 用于腹主动脉瘤治疗的三唑并[4, 5-d]嘧啶化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410139401.5A Pending CN103919781A (zh) 2007-12-03 2008-12-02 用于腹主动脉瘤治疗的三唑并[4, 5-d]嘧啶化合物

Country Status (24)

Country Link
US (2) US20100298350A1 (enExample)
EP (1) EP2229172B1 (enExample)
JP (1) JP5701060B2 (enExample)
KR (1) KR101563757B1 (enExample)
CN (2) CN101883565A (enExample)
AU (1) AU2008331984B2 (enExample)
BR (1) BRPI0819458A2 (enExample)
CA (1) CA2707488C (enExample)
CY (1) CY1115760T1 (enExample)
DK (1) DK2229172T3 (enExample)
EA (1) EA201000928A1 (enExample)
ES (1) ES2522317T3 (enExample)
HR (1) HRP20141081T1 (enExample)
IL (1) IL205613A (enExample)
MX (1) MX2010006101A (enExample)
MY (1) MY159656A (enExample)
NZ (1) NZ585513A (enExample)
PL (1) PL2229172T3 (enExample)
PT (1) PT2229172E (enExample)
RS (1) RS53635B1 (enExample)
SI (1) SI2229172T1 (enExample)
UA (1) UA100864C2 (enExample)
WO (1) WO2009072967A1 (enExample)
ZA (1) ZA201003599B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102653539A (zh) * 2011-03-01 2012-09-05 秦引林 一种抗血小板聚集化合物及其药物组合
CN103221413A (zh) * 2011-08-12 2013-07-24 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2750676B1 (en) 2011-08-30 2018-01-10 University of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003084A1 (en) * 1995-07-11 1997-01-30 Astra Pharmaceuticals Ltd. New inhibitors of platelet aggregation
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
WO2009007675A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102653539A (zh) * 2011-03-01 2012-09-05 秦引林 一种抗血小板聚集化合物及其药物组合
CN102653539B (zh) * 2011-03-01 2014-09-17 秦引林 一种抗血小板聚集化合物及其药物组合
CN103221413A (zh) * 2011-08-12 2013-07-24 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途
CN103221413B (zh) * 2011-08-12 2016-01-20 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途

Also Published As

Publication number Publication date
IL205613A0 (en) 2010-11-30
ES2522317T3 (es) 2014-11-14
PT2229172E (pt) 2014-11-03
SI2229172T1 (sl) 2014-12-31
WO2009072967A1 (en) 2009-06-11
EP2229172B1 (en) 2014-09-10
UA100864C2 (uk) 2013-02-11
HK1148195A1 (en) 2011-09-02
KR101563757B1 (ko) 2015-10-27
CA2707488A1 (en) 2009-06-11
ZA201003599B (en) 2012-10-31
NZ585513A (en) 2012-07-27
AU2008331984A1 (en) 2009-06-11
MX2010006101A (es) 2010-10-04
BRPI0819458A2 (pt) 2015-05-05
KR20100099175A (ko) 2010-09-10
HRP20141081T1 (hr) 2015-01-02
JP5701060B2 (ja) 2015-04-15
CY1115760T1 (el) 2017-01-25
PL2229172T3 (pl) 2015-01-30
DK2229172T3 (da) 2014-11-10
US20150272955A1 (en) 2015-10-01
EP2229172A4 (en) 2012-12-26
AU2008331984B2 (en) 2012-08-16
CA2707488C (en) 2015-07-28
EP2229172A1 (en) 2010-09-22
CN103919781A (zh) 2014-07-16
MY159656A (en) 2017-01-13
RS53635B1 (sr) 2015-04-30
IL205613A (en) 2015-04-30
EA201000928A1 (ru) 2010-12-30
JP2011505417A (ja) 2011-02-24
US20100298350A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
AU2015314830B2 (en) Cenicriviroc combination therapy for the treatment of fibrosis
WO2017048322A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
CN111904962A (zh) 含有PDE4抑制剂和PI3 δ或双重PI3 δ-γ激酶抑制剂的药物组合物
JP2023531863A (ja) 肺の機械的損傷によって促進される肺線維症状態の治療で使用するためのニューロキニン（ｎｋ）－１受容体拮抗薬
US20080188497A1 (en) Dipyridamole, Acetylsalicylic Acid, and Angiotensin II Antagonist Pharmaceutical Compositions
CA3234847A1 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
JP5701060B2 (ja) 腹部大動脈瘤の治療のためのトリアゾロ［４，５−ｄ］ピリミジン化合物
US20090048173A1 (en) Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors
US20090075949A1 (en) Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
TW202045180A (zh) 治療纖維化之方法
KR20080108156A (ko) 유기 화합물의 조합물
TWI344366B (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
KR102893744B1 (ko) 피리메타민을 유효성분으로 포함하는 류마티스 관절염의 치료 또는 예방용 약학 조성물
KR20250037531A (ko) 자가면역 질병의 치료약을 제조하기 위한 나프토퀸 포스페이트의 사용
WO2008022284A2 (en) Compositions and methods for treating vascular, autoimmune, and inflammatory diseases
HK1148195B (en) Ticagrelor for treatment of abdominal aortic aneurysms
US20130095059A1 (en) Inhaled no donor kmups derivative preventing allergic pulmonary vascular and bronchial inflammation via suppressed cytokines, inos and inflammatory cell counts in asthma model
TW202310839A (zh) 用於預防或治療纖維化之醫藥組成物
TW202313028A (zh) 使用s-羥氯喹的抗磷脂質症候群之治療
ITRM20110233A1 (it) Azitromicina, suoi sali o solvati farmaceuticamente accettabili per l?uso come neuroprotettori.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20101110